Peripheral blood mononuclear cells response to Lassa Virus and Mopeia/Lassa reassortant 29: time course
Summary:
Analysis of PBMCs exposed in vitro to LASV or ML29 viruses and collected up to 24 hrs post-exposure. The ML29 vaccine candidate is derived from Lassa and Mopeia viruses and protects against Lassa fever disease. Results provide insight into LASV-induced pathology and mechanisms of attenuation.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Zapata JC, Carrion R Jr, Patterson JL, Crasta O et al. Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate. PLoS Negl Trop Dis 2013;7(9):e2406. PMID: 24069471
